YD Bio

YD Bio OCF Margin

The Operating Cash Flow Margin of YD Bio (YDES) as of Oct 16, 2026 is -1,105.31 %. In the previous year, Operating Cash Flow Margin was -359.91 % — a change of 207.11% (lower).

OCF Margin

-1,105.31 %

YoY

207.11%

Last updated:

Operating Cash Flow Margin of YD Bio is 2025 -1,105.31 % . Operating Cash Flow Margin of YD Bio was 2024 -359.91 % . It decreases by 207.11% lower compared to the previous year.

The YD Bio OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2023
-15.90 USD
Jan 1, 2024
-359.91 USD
Jan 1, 2025
-1,105.31 USD
The YD Bio OCF Margin history
YEAROCF MarginYoY
-1,105.31 %+207.11%
-359.91 %+2,164.12%
-15.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

Operating Cash Flow Margin of YD Bio is -1,105.31 % in 2025.

Operating Cash Flow Margin of YD Bio changed from -359.91 % to -1,105.31 %, representing a 207.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin YD Bio since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's YD Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — YD Bio

All Key Metrics — YD Bio